Gilead Sciences Inc.’s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial. The ...
Impaired antibody response in an AIDS patient compromised the accuracy of the test. The OraQuick Advance Rapid HIV-1 Antibody Test has transformed HIV testing from a cumbersome process to a rapid ...
Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...
On Thursday, Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials ...
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received the ...
“Until there’s a cure or a vaccine, we will need to sustain the AIDS response beyond 2030,” UNAIDS Executive Director Winnie Byanyima said last month. When drugmaker Gilead Sciences announced interim ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV ...
Merck (NYSE:MRK) on Thursday indicated a mixed outcome in two pivotal Phase 3 trials for its experimental HIV therapy islatravir, administered orally in combination with its FDA-approved HIV therapy ...
Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid ...
Pharma stocks are back in focus as obesity drugs, HIV prevention and biotech deal activity shape the outlook heading into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback